1 Original article

Dengue clinical features and predictors of severity in the diabetic patient: a retrospective cohort study on Reunion island, 2019

- 5
- Azizah Issop ^a, Antoine Bertolotti ^{b,c}, Yves-Marie Diarra ^{b,d}, Jean-christophe Maïza ^a, Éric
 Jarlet ^a, Muriel Cogne ^a, Éric Doussiet ^{a,e}, Éric Magny ^f, Olivier Maillard ^b, Epidengue Cohort
 Investigation Team[¶], Estelle Nobécourt ^{a,b,g}, Patrick Gérardin ^{b,e,*}
- 9
- 10 ^a Service d'endocrinologie et diabétologie, Centre Hospitalier Universitaire Réunion, Saint
- 11 Pierre, La Réunion, France.
- ^b INSERM, CIC 1410, Centre Hospitalier Universitaire Réunion, Saint-Pierre, La Réunion,
- 13 France.
- 14 ^c Service des Maladies Infectieuses, Médecine Interne, Dermatologie, Centre Hospitalier
- 15 Universitaire Réunion, Saint Pierre, La Réunion, France.
- ^d UMR PIMIT (CNRS 9192, INSERM U1187, IRD 249, Université de La Réunion), Sainte
- 17 Clotilde, La Réunion, France.
- ^e Plateforme de Recherche Clinique et Translationnelle, Centre Hospitalier Universitaire,
- 19 Réunion, Saint-Pierre, La Réunion, France.
- 20 ^f Service de Biochimie, Centre Hospitalier Universitaire Réunion, Saint Pierre, La Réunion,
- 21 France.
- 22 ^g UMR Diabète Athérothrombose Thérapies Réunion Océan Indien (DéTROI) (INSERM
- 23 U1188), Plateforme CYROI, University of La Réunion, Sainte Clotilde, La Réunion, France.
- 24 * *Corresponding author:*
- 25 Dr Patrick GÉRARDIN
- 26 INSERM CIC1410 / Plateforme de Recherche Clinique et Translationnelle -
- 27 Centre Hospitalier Universitaire Réunion Groupe Hospitalier Sud Réunion BP 350 –
- 28 97448 Saint Pierre Cedex. Réunion island. France.
- 29 Tel : + 262 2 62 35 94 35 Mail: *patrick.gerardin@chu-reunion.fr*
- 30 Short running head title : **Dengue and severe dengue in the diabetic**
- 31 Manuscript credits : 4612 words, abstract 250 words, 4 tables (+ 5), 1 figure (+ 2), 42 references.

32 ABSTRACT

33

Aim: Diabetes mellitus is associated with both the risks of severe dengue and dengue-related
deaths, however the factors characterizing dengue in the diabetic patient are ill-recognized.
The objective of this hospital-based cohort study was to identify the factors characterizing
dengue and those able to predict dengue severity in the diabetic patient.

38

Methods: We retrospectively analysed demographic, clinical and biological parameters at
admission in the cohort of patients who consulted at the university hospital between January

- 41 and June 2019 with confirmed dengue. Bivariate and multivariate analyses were conducted.
- 42

43 Results: Of 936 patients, 184 patients (20%) were diabetic. One hundred and eighty-eight 44 patients (20%) developed severe dengue according to the WHO 2009 definition. Diabetic 45 patients were older and had more comorbidities than non-diabetics. In an age-adjusted logistic 46 regression model, loss of appetite, altered mental status, high neutrophil to platelet ratios 47 (>14.7), low haematocrit (\leq 38%), upper-range serum creatinine (>100 µmol/l) and high urea 48 to creatinine ratio (>50) were indicative of dengue in the diabetic patient. In a modified 49 Poisson regression model, four key independent variables were predictive of severe dengue in 50 the diabetic patient: presence of diabetes complications, non-severe bleeding, altered mental 51 status and cough. Among diabetes complications, diabetic retinopathy and neuropathy, but not 52 diabetic nephropathy nor diabetic foot, were predictive of severe dengue.

53

54 Conclusion: At hospital first presentation, dengue in the diabetic patient is characterized by 55 deteriorations in appetite, mental and renal functioning, while severe dengue can be predicted 56 by presence of diabetes complications, dengue-related non-severe haemorrhages, cough, and 57 dengue-related encephalopathy.

58

59 Keywords: Diabetes mellitus, Comorbidities, Dengue, Severe Dengue, Prognosis, Cohort60 study.

61 Introduction

62 Dengue virus (DENV) is the most common arbovirus circulating in the world [1]. In 63 2022, the European Center for Disease Prevention and Control (ECDC), reported from 64 different sources 4,110,465 dengue cases and 4,099 dengue-related deaths worldwide. DENV 65 affects mainly tropical countries of South America, Asia, Africa and Western Pacific [2]. 66 However, with the spread of the Aedes albopictus vector and the sharp increase in traveller 67 flows, it is no longer limited to the inter-tropical zone and dengue epidemics are also 68 documented in temperate regions [3]. In metropolitan France, where *Aedes albopictus* is 69 established and spreads since 2004, episodes of autochthonous dengue transmission occur 70 since 2010 [4, 5].

Reunion island, a French overseas department located in the south-western Indian ocean (SWIO) region, is particularly affected by DENV, which has been circulating under an epidemic mode since 2018. Thus, despite *Ae albopictus* related transmission may be considered as a distinct outlier associated with slow, low intensity outbreaks [6], 18,217 autochthonous cases have been notified to the island surveillance system in 2019, of which 1,944 occasioned visits to emergency wards and 620 ended in hospitalization [7].

The infection results in a wide spectrum of clinical manifestations that range from mild asymptomatic or paucisymptomatic infections, undifferentiated fever, dengue fever (DF) to severe dengue (SD), which is currently designated as severe plasma leakage, severe bleeding and/or severe organ involvement [8].

81 Predicting the occurrence of severe dengue in patients at risk remains a major public 82 health challenge. Overall, diabetes mellitus is known to increase the susceptibility to infection 83 [9] and diabetic patients tend to have a higher risk for infection-related mortality through 84 major cardiovascular events such as myocardial infarction and stroke [10, 11]. In addition, 85 diabetes was reported as a factor that drives the progression from DF to SD [12, 13]. With 86 respect to dengue, diabetes is therefore of paramount importance, and all the more so in 87 Reunion island, which is one of the French region with the highest prevalence of treated 88 diabetes (10% of the adult population, *i.e.*, twice the national average [14]).

The primary objective of this retrospective cohort study was twofold and aimed to identify both the factors characterizing dengue and those able to predict severe dengue in the diabetic patient among the subjects presenting at the hospital. The secondary objectives were to distinguish the clinical features of dengue among the subjects presenting with uncomplicated or complicated diabetes or presenting with optimal or suboptimal glycaemic control (glycated haemoglobin, HbA1c <7% or \geq 7%).

95 **Patients and methods**

96 Setting and population

We retrospectively enrolled in the cohort all patients with suspected dengue who
consulted at the university hospital between January 1 and June 30, 2019, and decided to
restrict the analyses to virologically confirmed cases of dengue.

100 Subjects were suspected of being infected with DENV if they had fever higher than 101 38°C and at least one of the following symptoms: headache, retro-orbital pain, myalgia, 102 arthralgia, rash, or pruritus. Dengue was confirmed if the patient had a positive detection of 103 DENV RNA by reverse transcriptase chain reaction (rt-PCR) and/or a positive detection of 104 non-specific antigen 1 (NS1) by Rapid Diagnostic Test (RDT). The diagnosis of SD was 105 made when the World Health Organization (WHO) 2009 criteria were met. Briefly, SD was 106 diagnosed in presence of: (1) severe plasma leakage leading to shock or respiratory distress, 107 (2) severe bleeding, or (3) severe organ involvement (e.g., high liver enzyme levels AST ALT 108 \geq 1000 IU/L, impaired consciousness, heart and other severe organ dysfunctions) [8]. The 109 criteria used for defining SD and the criteria used for defining severe organ involvement in 110 SD are detailed in the methodological appendix (S0 Table).

We systematically reviewed the medical records of all patients over 15 years admitted to the University Hospital of Reunion island for a clinical suspicion of dengue infection. We analysed in the cohort only the subjects with a confirmed diagnosis of dengue. For each patient with a confirmed dengue, it was verified that the hospital visit was related to the DENV infection. Thus, the patients hospitalized for another cause were ruled out.

We retrieved socio-demographic, clinical and biological data for each patient in the EPIDENGUE database, an electronic record based on the cross-referencing of data from the PMSI (*Programme de Médicalisation des Système d'Information*) and the laboratories completed by junior doctors. The biological data were collected at hospital first consultation.

Diabetes history was reported if documented and registered in the medical file and/orthe patient received an anti-diabetic treatment.

122

123 Statistical analysis

For bivariate analysis, quantitative variables were expressed as medians and interquartile ranges (1st - 3rd quartiles). Qualitative variables were expressed as numbers and percentages. Percentages were compared between diabetic patients (DPs) and non-diabetic patients (NDPs), and between severe and non-severe dengue cases using Chi-square and Fisher exact tests, as appropriate. Medians were compared between these groups using non-parametric

Brown-Mood tests [15]. Medians that were statistically different were further tested using median and quartile regressions to see whether they differ substantially both in precision and dispersion [16].

132 Subgroup analyses were conducted under the same modalities to assess both the 133 influence of complicated diabetes and of the control of blood sugar on dengue presentation.

Multivariate analyses were conducted first to identify the clinical and biological variables associated with diabetes among patients with dengue, second to find predictors of SD in the DP. In the first model, we used a non-conditional logistic regression model for estimating odds ratios (OR) and 95% confidence intervals (95%CI) of the factors independently associated with diabetes among the patients attending the hospital with dengue.

In the second model, we used the adapted Poisson regression model for binary outcome with robust variance option [17] for estimating the relative risks (RR) and 95%CI of the predictors of severe dengue in the DPs. In both analyses, we set *a priori* P, the maximum number of candidate variables (parameters) to be selected using the formula:

143

$P = \exp (0.508 - 0.259 \ln (\Box) + 0.544 \ln(\Box) + \ln(MAPE)/0.504),$

144 wherein \Box is the proportion of the outcome, n is the population size and MAPE, the mean 145 absolute prediction error [18]. In agreement with this method, we began with full models 146 controlling all variables with p values <0.025 in bivariate analyses (with socio-147 demographic/medical history and clinical data separate; clinical and biological data separate, 148 respectively). Each model was added to the other in an intermediate joined model (clinico-149 biological, or clinico-anamnestic, respectively) which was submitted to a stepwise backward 150 procedure that aimed at eliminating the less significant variables. Final parsimonious models 151 retained only significant covariates. However, as the prevalence of diabetes increases with 152 age, we forced age in the first final model. The fitness of the different models was evaluated 153 using the Bayesian Information Criterion (BIC). All interaction terms between the covariates 154 included in the final models were tested, likewise the effects of age and sex as potential 155 disease modifiers. Model calibration was evaluated using the Hosmer-Lemeshow goodness-156 of-fit test (also applied to the corresponding logistic model, when not applicable for Poisson 157 regression models). The discriminative capacity of the models was evaluated by the area 158 under the receiver operating characteristic curve (AUC). Analyses were performed using 159 Stata® (v16.1, StataCorp, College Station, Tx, 2019). For all these, observations with missing 160 data were ruled out and a two-tailed p value <0.05 was considered significant.

161

162 Ethical approval


163 This monocentric observational retrospective study was conducted according to the reference 164 methodology MR-004 from the National Commission of Informatics and Liberties. In 165 accordance with French regulations, this retrospective study did not require approval from an 166 ethics committee. The ethical character of the study on previously collected data was 167 approved by the Institutional Review Board of the Centre Hospitalier Universitaire Reunion. 168 The EPIDENGUE database was registered in the national health data hub (n° 169 F20201021104344). Patients were informed of the study and non-refusal of participation was 170 collected. Data was treated anonymously from patient's medical records.

- 171
- 172

173 **Results**

174 Dengue in the diabetic and non-diabetic patients

175 Between January 1, 2019, and the June 30, 2019, the surveillance system reported more 176 than 42,000 dengue illnesses on Reunion island, of which up to 18,000 were biologically 177 confirmed (>30,000 and >13,000 for the southern region alone, respectively). During this 178 period, the EPIDENGUE database enrolled 2,365 subjects clinically suspected of dengue 179 having presented at the two centres of the teaching hospital among whom this study included 180 936 patients with confirmed DENV infection (Fig. 1). Of these 936 patients, 184 were 181 diabetic and 752 non-diabetic. We did not distinguish between type 1 and 2 diabetes, given 182 the small number of patients primarily treated with insulin alone.



183

184 Figure 1. Study population

185

186 The most important differences between DPs and NDPs are presented in Table 1, while187 the full comparison between both populations is displayed in S1 Table.

DPs were older than NDPs (median age 70.0 years; Q_1 - Q_3 : 59.4-77.7 *versus* 45.6 years, Q₁-Q₃: 29.7-63.0, *p*<0.001). The proportion of women was similar in both populations. Comorbidities were more frequent in DPs and ranged between 5.4% for peptic ulcer and 70.6% for hypertension (p<0.01 for all comparisons), which resulted in higher Charlson comorbidity index scores among DPs than among NDPs (median score 5; Q₁-Q₃: 3-7 *vs* 0, Q₁-Q₃: 0-3, *p*<0.001) and more common use of related medications (S1 Table).

Table 1. Characteristics at hospital presentation of 936 virologically confirmed cases of dengue among non-diabetic and diabetic patients, Reunion island, January to June 2019.

Variable	Total Non-diabetic par (NDPs)						
	n=936	(%)	n=752	(%)	n=184	4 (%)	p value
Socio-demographic							
Age (years ; medians, Q_1 - Q_3)	51.9	(32.7 - 69.7)	45.6	(29.6 - 63.1)	70.0	(59.4- 77.7)	***< 0.001
Female sex	540	(57.7)	438	(58.2)	102	(55.4)	0.489
Comorbidities							
High blood pressure	294	(31.4)	164	(21.8)	130	(70.6)	< 0.001
Dyslipidaemia	91	(9.7)	33	(4.4)	58	(31.5.)	< 0.001
Chronic kidney disease	68	(7.3)	28	(3.7)	40	(21.7)	< 0.001
Charlson score (medians, Q1-Q3)	1	(0 – 3)	0	(0 - 2)	5	(3 - 7)	***< 0.001
Clinical features at presentation							
Days from symptom onset							
≤3	602	(68.7)	468	(66.9)	134	(75.7)	0.025
> 3	274	(31.3)	231	(33.1)	43	(24.3)	
Indicators of probable dengue							
Skin rash	148	(15.8)	135	(17.9)	13	(7.1)	< 0.001
Other manifestations							
Muco-cutaneous signs	187	(20.0)	169	(22.5)	18	(9.8)	< 0.001
Cardiorespiratory signs	170	(18.2)	125	(16.6)	45	(24.5)	0.013
Altered mental status	80	(8.6)	44	(5.9)	36	(19.6)	< 0.001
Biology at presentation (medians, Q1	-Q ₃)						
ALT (IU/I)	26	(16 - 49)	34	(20 - 71)	40	(20 - 88)	0.310
AST (IU/I)	37	(24 - 72)	36	(24 - 71)	42	(24 - 79)	0.257
C reactive protein (mg/l)	10.8	(4.7 - 23.8)	8.6	(3.9 - 20.7)	18.3	(8.7 - 31.7)	< 0.001
Chlorine (mmol/l)	99	(96 - 101)	100	(97 - 102)	97	(94 - 100)	< 0.001
CPK (IU/I)	127	(80 - 230)	126	(80 - 219)	140	(76 - 275)	0.397
Creatinine (µmol/l)	85	(69 - 106)	81	(67 - 99)	104	(78 - 135)	***<0.001
Fibrinogen (g/l)	3.6	(3.1 - 4.2)	3.5	(3.1 - 4.1)	4.0	(3.5 - 4.5)	< 0.001
Haematocrit (%)	40.0	(36.4 - 43.4)	40.5	(37.1 - 43.8)	37.9	(34.8 - 41.7)	< 0.001
Haemoglobin (g/dl)	13.5	(12.3 - 14.9)	13.7	(12.5 - 15.1)	12.7	(11.6 - 14.2)	< 0.001
Leucocytes (G/I)	4.2	(2.9 - 6.0)	4.0	(2.8 - 5.6)	5.0	(3.5 - 7.5)	< 0.001
Lipase (IU/I)	33.9	(23.3 - 50.5)	32.6	(23.2 - 47.9)	38.5	(24.0 - 58.3)	**0.028
Monocyte to platelet ratio	3.1	(2.0 - 5.0)	2.9	(1.8 - 4.6)	3.8	(2.5 - 6.7)	*0.001
Monocytes (G/I)	0.5	(0.3 - 0.7)	0.5	(0.3 - 0.7)	0.6	(0.4 - 0.8)	< 0.001
Neutrophil to lymphocyte ratio	4.2	(2.2 - 8.7)	3.8	(2.0 - 7.7)	5.5	(2.8 - 10.7)	*0.008
Neutrophil to platelet ratio	19.4	(11.8 - 30.3)	18.2	(11.0 - 28.2)	25.8	(16.5 - 38.7)	< 0.001

Neutrophils (G/I)	2.8	(1.7 - 4.5)	2.6	(1.6 - 4.2)	3.4	(2.1 - 5.4)	*0.002
Platelets (G/I)	154	(107 - 202)	157	(109 - 204)	152	(101 - 195)	0.397
Potassium (mmol/l)	3.9	(3.6 - 4.2)	3.8	(3.6 – 4.1)	4.1	(3.7 – 4.5)	**< 0.001
Sodium (mmol/l)	137	(134 - 139)	137	(135 - 139)	136	(133 - 138)	< 0.001
Troponin (ng/l)	0.1	(0.1 - 0.3)	0.1	(0.1 - 0.3)	0.2	(0.1 - 0.6)	0.019
Urea (mmol/l)	4.6	(3.3 – 6.5)	4.2	(3.0 - 5.8)	6.5	(4.8 - 9.6)	***<0.001
Urea to creatinine ratio	52	(41 - 65)	50	(40 - 63)	60	(49 - 76)	< 0.001

[†]This variable sums the numbers of probable dengue indicators and warning signs. Data are numbers and column percentages, or medians and interquartile ranges (Q1-Q3) when specified. Percentages are compared using chi2 or Fisher's Exact test, as appropriate. Medians are compared using a non-parametric Brown-Mood k-sample test and when it was significant, further with median and quartile regressions. * p< 0.05, ** p<0.01 and *** p<0.001 for the less significant of both quantile regressions (no * means that at least one quantile regression is not significant).

194

DPs reported more frequently fever, fatigue, loss of appetite, and less frequently myalgia within the days preceding first hospital presentation than NDPs. At first consultation, they were more febrile, more tachycardic and exhibited higher systolic and mean blood pressures than NDPs but the differences were not substantial to make sense clinically, as evidenced by inconsistent quantile regression coefficients.

Over the course of the dengue episode, DPs presented earlier to hospital than NDPs (75.7% *vs* 66.9%, within 3 days of symptom onset, p=0.025). Dengue in the diabetic was characterized at presentation by more common cardiorespiratory signs and altered mental status but fewer muco-cutaneous signs.

204 Biologically, DPs had lower haematocrit and haemoglobin levels, but higher leucocyte 205 counts than NDPs at presentation. However, the differences in white blood cell related 206 parameters were substantial only for neutrophil count, the neutrophil to lymphocyte ratio 207 (NLR), and the monocyte to platelet ratio (MPR), which higher values were potential 208 indicators of dengue in the DP. Other biological parameters substantially associated with 209 dengue in the DP include higher neutrophil to platelet ratio (NPR), neutrophil to 210 lymphocyte*platelet ratio (NLPR), lipase, potassium, urea, and creatinine levels, while 211 international normalized ratio, fibrinogen, sodium, chloride, urea to creatinine ratio, or C-212 reactive protein levels exhibited also significant differences in medians but not over the whole 213 extent of their distributions. Noteworthy, there were no significant differences between the 214 two groups for platelet counts and liver enzymes levels at presentation.

The abovementioned stringent selection procedure of covariates characterizing dengue in the DP identified four symptoms, three clinical features and four biological parameters, as potential indicators of dengue in the diabetic at first presentation (Table 2).

9

		Bivariate analysis Multivar n = 936 (2 separate		te analysis full models) ^{1,2}	Multivariate analysis (Intermediate joined model) ³		Multivariat (Final joine	
Variables	Crude OR	(95% CI)	Adjusted OR	(95% Cl)	Adjusted OR	(95% CI)	Age-Adjusted OR	(95% CI)
Symptoms (within 7 days)		. ,	-	. ,	-	. ,	• •	. ,
Fever	2.00	(1.20 - 3.33)	2.00	(1.15 - 3.44)	2.56	(1.01 - 6.42)	-	-
Fatigue	1.59	(1.10 - 2.28)	1.10	(0.71 - 1.68)	-	-	-	-
Loss of appetite	1.94	(1.40 - 2.70)	1.92	(1.30 - 2.82)	2.01	(1.32 - 3.06)	1.97	(1.28 - 3.02)
Myalgia	0.68	(0.49 - 0.95)	0.65	(0.45 - 0.93)	0.85	(0.54 - 1.31)	-	-
Clinical features at presentation						. ,		
Muco-cutaneous signs	0.37	(0.22 - 0.63)	0.34	(0.20 - 0.58)	0.43	(0.23 - 0.77)	-	-
Altered mental status	3.91	(2.43 - 6.29)	3.10	(1.86 - 5.16)	3.47	(1.92 - 6.25)	2.08	(1.16 - 3.72)
Cardiorespiratory signs	1.62	(1.10 - 2.39)	1.30	(0.87 - 1.95)	-	- /	-	· - /
Biology at presentation								
Haematocrit (%)								
≤ 38	2.02	(1.31 - 3.13)	2.24	(1.39 - 3.59)	2.12	(1.30 - 3.45)	2.00	(1.16 - 3.71)
> 42	0.68	(0.41 - 1.13)	0.64	(0.37 - 1.07)	0.60	(0.34 - 1.05)	0.66	(0.36 - 1.19)
Neutrophil to platelet ratio		(/		,		()		()
14.8 – 28.1	2.03	(1.24 - 3.31)	2.44	(1.43 - 4.14)	2.58	(1.50 - 4.44)	2.19	(1.27 - 3.76)
> 28.1	3.78	(2.32 - 6.13)	4.46	(2.61 - 7.61)	4.14	(2.38 - 7.19)	3.27	(1.81 - 5.86)
Serum creatinine (µmol/l)		· · · ·		· · · ·		· · · ·		,
71-100	1.73	(1.00 - 2.98)	-	-	-	-	1.33	(0.69 - 2.55)
> 100	5.18	(3.05 - 8.78)	-	-	-	-	2.29	(1.17 - 4.48)
Serum urea to creatinine ratio		. ,						. ,
46-100	3.16	(1.97 - 5.06)	3.23	(1.96 - 5.29)	2.79	(1.66 - 4.70)	2.02	(1.18 - 3.44)
> 100	8.16	(3.62 - 18.39)	6.64	(2.78 - 15.90)	6.18	(2.53 - 15.11)		(1.18 - 7.78)

Table 2. Clinical and biological characteristics found at hospital presentation in the diabetic patients with virologically confirmed cases of dengue, Reunion island, January to June 2019

OR: odds ratio. 95%CI: 95% confidence interval.

¹ The full clinical logistic regression model is based on 936 subjects which represents 100% of the observations. Akaike information criterion (AIC): 0.928. Bayesian information criterion (BIC): - 5496. Hosmer-Lemeshow goodness-of-fit : *p* value = 0.762. Area under the receiver operating characteristic curve (AUC) : 0.692 (95%CI: 0.648 -0.734).

² The full biological logistic regression model is based on 723 subjects which represents 77% of the observations. AIC: 0.915. BIC: - 4065. Hosmer-Lemeshow goodness-of-fit : p value = 0.405. AUC : 0.752 (95%CI: 0.710 - 0.794).

³The intermediate clinic-biological logistic regression model is based on 723 subjects which represents 77% of the observations. AIC: 0.868. BIC: - 4077. Hosmer-Lemeshow goodness-offit : p value = 0.970. AUC : 0.793 (95%CI: 0.753 – 0.833).

⁴ The final clinic-biological logistic regression model is based on 723 subjects which represents 77% of the observations. AIC: 0.821. BIC: - 4111. Hosmer-Lemeshow goodness-of-fit : *p* value = 0.322. AUC : 0.825 (95%CI: 0.789 – 0.861).

218 Pre-existing chronic conditions and their related treatments were deemed indicative of219 diabetes comorbidities and not eligible to this analysis.

The three-step multivariate analysis identified fever, loss of appetite and altered mental status as independent clinical indicators, and low haematocrit (\leq 38%), high NPR ratio (\geq 14.8), upper-range creatinine (\geq 100 µmol/l) and high serum urea to creatinine (> 45) as independent biological indicators of dengue in the diabetic, whereas myalgia and mucocutaneous signs were associated with dengue in the NDPs (data not shown).

In the pre-final joined model, adjusting for age abrogated the association between muco-cutaneous signs and NDPs (data not shown). The final age-adjusted joined model confirmed six independent indicators of dengue in the diabetic: loss of appetite (adjusted OR 1.97, 95%CI 1.28-3.02), altered mental status (aOR 2.02, 95%CI 1.28-3.02), low haematocrit (aOR 2.00, 95%CI 1.16-3.71), high NPR (aOR 2.19 in the intermediate tercile, aOR 3.27 in the upper tercile), upper-range creatinine (aOR 2.02, 95%CI 1.28-3.02) and high serum urea to creatinine ratio (aOR 2.02 in the intermediate tercile, aOR 3.04 in the upper tercile).

232

233 Dengue in diabetic patients with or without diabetes complications

When compared to uncomplicated diabetes, dengue of the DPs with complicated diabetes occurred in older and highly comorbid subjects (S2 Table). At presentation, it was clinically unremarkable but characterized by higher serum creatinine level and slightly lower haematocrit, haemoglobin, or ALT levels. However, upon hospitalization, it was marked by higher peak C reactive protein and higher odds to evolve towards SD.

When compared to NDPs, DPs with diabetes complications exhibited more frequent dehydration, more clinical fluid accumulation and more haemoconcentration. Loss of appetite and altered mental status, indicators of inflammation or renal dysfunction were found in DPs, irrespective of the severity of diabetes.

The full abnormalities found given the severity of diabetes are displayed in S1 Fig.

244

245 Dengue in diabetic patients with optimal or suboptimal glycaemic control

When compared to diabetes with optimal control (HBA1c <7%), dengue of the DP with suboptimal glycaemic control (HBA1c \geq 7%) at presentation (S3 Table) was also clinically unremarkable but biologically characterized by higher MPR, lower sodium and chlorine levels.

11

When compared to NDPs, DPs with suboptimal glycaemic control expressed roughly the same particularities than DPs with clinically complicated diabetes, which showed a fairly overlap between clinical and biological diabetes disease markers.

- 253 The full abnormalities found given the control of diabetes are displayed in S2 Fig.
- Taken together, these data suggest that thrombocytopenia (platelet counts < 100 G/l) in
- the diabetic patient was more likely indicative of an uncomplicated diabetes with suboptimal
- 256 glycaemic control rather than a complicated diabetes.
- 257

258 Predictors of severe dengue in the diabetic patients

259 The most important differences between DF (hereafter designated as non-severe

dengue) and SD in the DPs are presented in Table 3, while the full comparison between both

261 populations is displayed in S4 Table.

262

Table 3. Characteristics at hospital presentation of virologically confirmed cases of non severe and severe dengue cases among diabetic patients, Reunion island, January to June 2019.

Variable	Total		Non se	vere dengue (DF)	Severe dengue (SD)		
	n=184	(%)	n=124	(%)	n=60	(%)	p value
Socio-demographic							
Age (years ; medians, Q1-Q3)	70.0	(59.4 - 77.7)	70.0	(58.6 - 77.3)	69.6	(60.6 - 78.4)	0.875
Female sex	102	(55.4)	68	(54.8)	34	(56.7)	0.815
Comorbidities							
Chronic kidney disease	40	(21.7)	21	(16.9)	19	(31.7)	0.023
Charlson score (medians, Q1-Q3)	5	(3 - 7)	4	(3 - 6)	6	(3 - 8)	0.018
Symptoms (within 7 days)							
Backache	34	(18.5)	28	(22.6)	6	(10.0)	0.039
Clinical features at presentation							
Indicators of probable dengue							
Body aches	124	(67.4)	90	(72.6)	34	(56.7)	0.031
Warning signs							
0	116	(63.0)	83	(66.9)	33	(55.0)	0.079
1	52	(28.3)	34	(27.4)	18	(30.0)	
>1	16	(8.7)	7	(5.7)	9	(15.0)	
Clinical fluid accumulation (n=155)	12	(7.7)	3	(2.9)	9	(17.0)	0.003
Other manifestations							
Dehydration	69	(37.5)	40	(32.3)	29	(48.3)	0.035
Cardiorespiratory signs	45	(24.5)	18	(14.5)	27	(45.0)	< 0.001
Altered mental status	36	(19.6)	18	(14.5)	18	(30.0)	0.013
Non severe bleeding	21	(11.4)	9	(7.3)	12	(20.0)	0.011
Cough	17	(9.2)	7	(5.6)	10	(16.7)	0.016
Biology at presentation (medians, Q1	-Q ₃)						
Neutrophil to lymphocyte ratio	5.5	(2.8 - 10.7)	6.5	(3.2 - 10.8)	4.2	(2.5 - 10.2)	0.039
AST (IU/I)	42	(24 - 79)	37	(22 - 70)	46	(31 - 103)	0.070
ALT (IU/I)	26	(16 - 52)	23	(14 - 43)	37	(20 - 66)	0.216
Alkaline phosphatase (IU/I)	73	(55 - 91)	62	(54 - 87)	80	(72 - 106)	0.015
Potassium (mmol/l)	4.1	(3.7 - 4.5)	4.0	(3.7 - 4.3)	4.3	(3.8 - 4.7)	0.008

Data are numbers and column percentages, or medians and interquartile ranges (Q1-Q3) when specified. Percentages are compared using chi2 or Fisher's Exact test, as appropriate. Medians are compared using a non-parametric Brown-Mood k-sample test and when it was significant, further with median and quartile regressions. * p < 0.05, ** p < 0.01 and *** p < 0.001 for the less significant of both quantile regressions (no * means that at least one quantile regression is not significant).

Age and gender distributions did not differ between DPs with SD and DPs with nonsevere dengue.

DPs with SD were more frequently affected by chronic kidney disease (CKD, 31.7% *vs* 16.9%, p=0.023) and higher Charlson comorbidity index scores (median score 6; Q_1 - Q_3 : 3-8 *vs* 4, Q_1 - Q_3 : 3-6, *p*=0.018) than DPs with non-severe dengue.

Backache was less frequently reported in DPs with SD than in DPs with non-severe dengue. DPs with SD suffered less body aches but experienced more commonly non-severe bleeding, fluid accumulation, dehydration, cardiorespiratory signs (including cough) and altered mental status at presentation.

Biologically, DPs with SD exhibited lower median neutrophil to lymphocyte ratios but higher median phosphatase alkaline and potassium levels than DPs with non-severe dengue at presentation. However, these differences were not observed over the whole extent of variable distributions. Other biological parameters were similar between the two groups.

The selection procedure of covariates predictive of SD in the DPs identified diabetes complications (*i.e.*, diabetes with retinopathy and/or neuropathy and/or nephropathy and/or diabetic foot), CKD (especially when alleged of non-diabetic origin), untreated hypertension and entrenched-proxy Charlson comorbidity index (*i.e.*, Charlson score subtracted from diabetes-associated points) as potential comorbidities, non-severe bleeding, presence of warning signs, altered mental status or cough as potential early clinical features predictive of severe dengue in the DPs at presentation (Table 4).

	Bivariate analysis		Multivaria	te analysis	Multivariate analysis		
			(2 separate f	ull models) ^{1,2}	(1 final joined model) ³		
Variables	Crude RR	(95% CI)	Adjusted RR	(95% CI)	Adjusted RR	(95% CI)	
Comorbidities							
Diabetes complications *	1.84	(1.23 - 2.75)	1.74	(1.10 - 2.75)	2.06	(1.39 - 3.05)	
Chronic kidney disease of undifferentiated origin	1.67	(1.10 - 2.53)	-	-	-	-	
Chronic kidney disease alleged of diabetic origin	1.45	(0.89 - 2.36)	-	-	-	-	
Chronic kidney disease alleged of non-diabetic origir	1.74 1	(1.00 - 3.01)	1.66	(0.82 - 3.36)	-	-	
Untreated hypertension	1.85	(1.13 - 3.02)	1.43	(0.84 - 2.41)			
Entrenched-proxy Charlson comorbidity score **	1.09	(1.00 - 1.17)	1.01	(0.90 - 1.13)			
Clinical features at presentat	tion						
Warning signs ***							
1	1.22	(0.75 - 1.95)	1.25	(0.75 - 2.07)	-	-	
> 1	1.98	(1.17 - 3.33)	1.57	(0.82 - 3.04)	-	-	
Non severe bleeding	1.94	(1.24 - 3.02)	1.65	(0.91 - 2.95)	2.34	(1.49 - 3.67)	
Altered mental status	1.76	(1.16 - 2.67)	1.71	(1.15 - 2.54)	1.69	(1.15 - 2.50)	
Cough	1.96	(1.23 - 3.12)	1.91	(1.18 - 3.07)	1.95	(1.25 - 3.06)	

Table 4. Anamnestic and clinical predictors of severe dengue at hospital presentation of a diabetic patient with virologically confirmed dengue (RT-PCR+ or NS1 antigen+), Reunion island, January to June 2019

* Diabetic retinopathy and/or diabetic neuropathy and/or diabetic nephropathy and/or diabetic foot.

**The Charlson comorbidity score was entrenched (or reduced) of the points provided by diabetes and chronic kidney disease to allow the adjustment of the score with these factors without overfitting the model.

*** Abdominal pain or tenderness, persistent vomiting, clinical fluid accumulation, mucosal bleed, lethargy or restlessness, liver enlargement > 2 cm, increase in haematocrit concurrent with rapid decrease in platelet count.

RR: relative risk. 95%CI: 95% confidence interval.

¹ The full anamnestic Poisson regression model is based on 184 subjects which represents 100% of the observations. Akaike information criterion: 1.393. Bayesian information criterion: - 687. Area under the receiver operating characteristic curve (AUC) : 0.636 (95%CI: 0.547 - 0.725).

² The full clinical Poisson regression model is based on 184 subjects which represents 100% of the observations. AIC: 1.386. BIC: - 685. AUC : 0.675 (95%CI: 0.592 - 0.757).

³ The final clinic-anamnestic Poisson regression model is based on 184 subjects which represents 100% of the observations. AIC: 1.343. BIC: - 696. AUC: 0.725 (95%CI: 0.648 - 0.802).

284

- 285 The final joined model identified four key independent predictors of severe dengue in
- the DPs: diabetes complications (adjusted RR 2.06, 95%CI 1.39-3.05), non-severe bleeding
- 287 (aRR 2.34, 95% CI 1.49-3.67), altered mental status (aRR 1.69, 95% CI 1.15-2.50) and cough.
- Among diabetes complications, diabetic retinopathy (16.7% vs 7.2%, p=0.049), and
- 289 neuropathy (16.7% vs 5.5%, p=0.016) but not diabetic nephropathy (25.0% vs 14.5%,
- p=0.082) nor diabetic foot (3.1% vs 1.6%, p=0.597) were predictive of severe dengue.

291 Discussion

To the best of our knowledge, this retrospective cohort study is the first that attempted to both characterize dengue and to identify predictors of severe dengue in the diabetic patient.

294

295 Key findings

The first model identifies six independent indicators of dengue in the DPs, namely loss of appetite, altered mental status, low haematocrit (\leq 38%), high neutrophil to platelet ratio (\geq 14.8), upper-range creatinine (> 100 µmol/l), and high serum urea to creatinine ratio (> 45). To a lesser extent, this model also showed that muco-cutaneous signs were indicative of dengue in the NDPs, but the association did not resist to age adjustment.

The second model proposes four key predictors of SD in the DPs, namely diabetescomplications, non-severe bleeding, altered mental status and cough.

303

304 Strengths and limitations

305 This study has several strengths. First, the cohort was extracted from the EPIDENGUE 306 database, a quasi-exhaustive register of all dengue cases having consulted at the University 307 hospital in 2019, which allows our study population to be considered as representative of a 308 hospital dengue-infected population in Reunion. Second, the cohort was recruited during a 309 single dengue seasonal epidemic in the hospital setting, which ensures, theoretically, a 310 relative homogeneity in the definition and classification of dengue cases, especially as the 311 Reunionese population was naïve to dengue on the study period. Third, with respect to the 312 topic, the study sample was relatively important, and the selection method of candidate 313 indicators/predictors was rigorous, which allowed the possibility of conclusive multivariate 314 models on both aspects of the analysis. Fourth, the two final multivariate models displayed 315 acceptable metrics both in terms of fitness, calibration, and discrimination, which confers 316 internal validity to the analysis.

317 This study has also some limitations. First, given the retrospective character of this 318 cohort study, the study may be prone to reporting bias (i.e., mainly underreporting of 319 exposure/events), which may have hampered the completeness of the data and be the source 320 of subsequent information or evaluation biases, this depending on whether it is an exposure or 321 an outcome variable which is affected. Second, this hospital-based study might have been also 322 submitted to a potential selection or referral bias, given the only hospital recruitment of 323 dengue cases. However, we believe this do not really stand for most of the DPs, diabetes 324 being recognized as a risk factor of severe infection for most emerging infectious diseases

[19-21]. This may have been incentive for the primary care physician to refer the DPs of
suspected dengue to the hospital, as suggested by high hospitalization rates including for DPs
with uncomplicated diabetes.

328

329 Interpretation

330 Diabetic patients represented 19.6% of the study population. This proportion overlaps 331 more or less the figure expected in the Reunion island adult population, given former 332 estimates of the prevalence of diabetes at 20.1% in the Reunionese aged 30 to 69 [22]. DPs 333 were older and more comorbid than NDPs, which may illustrate the fact that diabetes is an 334 age-related disease that along with aging tends to cluster other chronic conditions. This 335 element might have skewed the DPs towards higher proportions of complicated diabetes as 336 compared to the overall population of diabetics observed on the island. In addition, some DPs 337 may have been referred to the hospital by their primary care physician because they had 338 comorbidities or warning signs, or need to upgrade the antidiabetic medication (e.g., insulin in 339 support to oral treatment).

DPs with dengue were more likely to present loss of appetite than NDPs, which could suggest the presence of subclinical exocrine pancreatitis in some patients [23]. Consistent with this, we found among DPs with loss of appetite, higher lipase levels, more common nausea/vomiting, and non-significant trends towards more persistent vomiting or abdominal tenderness than in DPs without anorexia (data not shown). Whether this may be attributable to dengue or diabetes, or both, cannot be assessed from our data.

346 DPs with dengue exhibited more commonly altered mental status (*i.e.*, confusion, 347 behavioural changes, or other cognitive impairments), the major criterion for defining 348 encephalitis [24]. This finding was unrelated to several potential indicators of plasma leakage, 349 endothelial activation or systemic inflammation in stratified analysis (e.g., 350 haemoconcentration, fluid accumulation, NLR, PLR) but coherent with that observed in West 351 Nile flavivirus encephalitide, for which diabetes is a known risk factor [25].

DPs with dengue had lower haematocrit than NDPs, which correlated with lower haemoglobin and higher C reactive protein levels and was potentiated by CKD. Together, this finding would better account for inflammatory anaemia due to diabetes (especially if complicated with nephropathy) rather than for a proper effect of dengue [26]. Alternatively, DPs with complicated diabetes exhibited also more haemoconcentration than NPDs, which raises the interest in new biomarkers of fluid accumulation than the haematocrit alone (or the

haematocrit plus the rapid platelet count fall) to better assess the plasma leakage in this population.

360 Interestingly, DPs with dengue displayed a higher NPR, a predictor that has been linked 361 to dengue mortality or need for critical care in our setting [27]. To the best of our knowledge, 362 this ratio had not been used previously in dengue neither for diagnosis nor for prognosis 363 purpose. Given it was correlated both to NLPR and NLR (data not shown), we hypothesize 364 that it could be indicative of both systemic inflammation [28] and early platelet-neutrophil 365 interactions aimed at clearing the virus through neutrophil extracellular traps (NETs), this 366 latter mechanism to be triggered by activated platelets in dengue [29] but also well-known to 367 be at work in diabetes through a different pathway [30]. In addition, a high NPR at hospital 368 presentation was later associated with thrombocytopenia and lower platelet nadirs when the 369 full hospital stay was considered (data not shown), which may support shared, or even 370 additive, mechanisms in both diabetic and SD patients in the pathogenesis of 371 thrombocytopenia.

372 Dengue in the DPs was independently associated with both organic and functional 373 components of acute kidney injury, as suggested by higher serum urea to creatinine ratio and 374 higher serum creatinine level than in NDPs. However, subsequent stratified analyses (data not 375 shown) revealed that in DENV-infected DPs with CKD, only the organic component was 376 prevailing, which contrasted with NDPs with CKD for which the two components contributed 377 to DENV-driven deterioration in renal function. Taken together, these data may illustrate the 378 multifactorial mechanism of dengue-related acute kidney injury [31] and the greater 379 sensitivity of the diabetic kidney to DENV infection [32].

380 Finally, this study proposes the presence of diabetes complications as an independent 381 predictor of SD for the DP from a model controlling the other comorbidities, warning signs, 382 and three early predictors of SD. Importantly, the model reveals that diabetes supplants all 383 other comorbidities in the development of SD, especially hypertension and CKD, two other 384 highly prevalent chronic conditions on the island [33, 34]. It also suggests that DPs with 385 complicated diabetes are prone to all three modes of entry into SD, namely severe bleeding, 386 severe plasma leakage with respiratory distress, and severe central nervous system 387 involvement, with non-severe bleeding, cough and altered mental status, as respective 388 harbingers. Consistent with this hypothesis, these harbingers were associated with more 389 severe related organ dysfunctions in subsequent analyses (e.g., cough with acute lung injury, 390 data not shown).

391 Among the mechanisms raised to promote the aggravation of dengue in the DP, 392 apoptosis of leucocytes and endothelial microvascular cells has been proposed from post-393 mortem findings [35], while more recently, a mouse model unravelled the role of 394 hyperglycaemic stress to facilitate DENV replication through the poly(A)-binding protein 395 PI3K/AKT signalling [36]. Together with the microvascular and macrovascular damages of 396 diabetes complications, this would increase the susceptibility of the DPs to the severe plasma 397 leakage key to SD pathogenesis [37]. In our study, the lack of correlates within the subgroups 398 of complicated diabetes and DPs with known HbA1c levels deters to propose a putative 399 mechanism. Nevertheless, we assume that the higher MPR found in DPs with HbA1c \geq 7% 400 than that observed in DPs with HbA1c <7% might reflect more intense trafficking of 401 monocytes under monocyte chemoattractant protein-1 secretion induced by activated platelets 402 [35, 38], which might also increase endothelial dysfunction and support more severe plasma 403 leakage in the DP with suboptimal control [39].

404

405 Generalizability

406 Notwithstanding the monocentric nature of this hospital-based study,
407 several results echo observations published in the literature and suggest that some of its
408 findings could be extrapolated, at least to other DENV-2 epidemics in similar contexts.

409 First, we confirm that diabetes outweighs the other comorbidities in promoting the 410 pathogenesis of SD, which is consistent with the meta-analysis by Sangkaew et al. that 411 showed the highest pooled OR for diabetes in the progression from DF to SD in random-412 effects models controlling prognostic factors [40]. Moreover, our findings support the 413 importance of diabetes control aimed at preventing its vascular complications to avoid SD. 414 Together, these elements corroborate the results of Pang et al. in Singapore and of Lee et al. in 415 Taiwan who have shown, both in populations mainly affected by DENV-2 that only DPs with 416 additional comorbidities, especially hypertension, were at increased risk of severe forms of 417 dengue [13, 39].

Second, the study confirms the importance of non-severe bleeding disorders in the DPs as a predictor of SD, which is consistent with studies identifying diabetes as a risk factor for dengue haemorrhagic fever (WHO 1997 classification) [13] or a risk factor for SD (WHO 2009 classification) [39]. Surprisingly, we did not find lower admission platelet counts in DPs than in NDPs, which differs from the recent observation by Singh et al. in India [37] and another one in Taiwan. However, on Reunion island, DPs exhibited lower platelet nadir than NDPs upon hospitalization, which may relate the discrepancy between studies to the earlier

presentation in the course of illness of DPs (75% within 3 days post-symptom onset). Indeed,
platelet nadir during dengue usually occurs within 4-5 days (48 hours of the critical phase)
and our observation of a platelet nadir at day 2 in DPs lends to support to this explanation.

428 Third, we identified altered mental status, as a predictor of SD in the DPs, which is 429 consistent with the increased odds of intracranial haemorrhage or cerebral infarction found 430 among Taiwanese patients with dengue and altered consciousness in multivariate analyses 431 controlling potential comorbidities [41]. Interestingly, DPs represented a third of their study 432 sample, and one model adjusted for a Charlson score >4, which matches 60% of DPs and 96% 433 of DPs with complicated diabetes in our study. Beyond the mode of entry into dengue 434 encephalitis, this raises the possibility that our second model may apply to predict severe 435 central nervous involvement, as results of haemorrhagic or thrombotic events, more frequent 436 in the DPs.

Fourth, we identified cough as a predictor of SD in the DPs. Although respiratory tract involvement is uncommon in dengue, cough has been reported in approximately 25–50% of DF cases. This result is consistent with the Thai report by Temprasertrudee, which identified cough as an independent predictor of SD in a model controlling alanine aminotransferase levels [42].

Last, the findings of the study evidences a close relationship between diabetes and renal dysfunction among dengue patients which may support diabetes as risk factor for acute dengue-related kidney injury [32], even though such a study remains to be done in our context.

446

447 Implications

For individual health purposes, this study may help patient management through better characterization of dengue and identification of early prognostic factors of SD in the DPs. Indeed, this should encourage emergency physicians during epidemic periods to refine the triage of patients consulting the emergency department and propose more intense monitoring of DPs with diabetes complications to allow earlier hospitalization whenever needed.

For public health purposes, this study should motivate more active screening strategies of both conditions among people living in or travelling to dengue endemic countries and emphasize the DPs with complicated diabetes as a candidate for dengue vaccine immunization.

457 For research purposes, this study should help to design future studies aimed at 458 investigating the interactions between diabetes and dengue and the concept of syndemic.

There are several arguments for a double negative impact of both affections each on the other and understanding the short-term and long-term consequences of dengue in the DP deserves certainly further studies.

462

463 Conclusion

464 At hospital first presentation, dengue in the diabetic patient is characterized by 465 deteriorations in appetite, mental and renal functioning, while severe dengue can be predicted 466 by diabetes complications, dengue-related non-severe haemorrhages, cough, and dengue-467 related encephalopathy. Larger prospective studies are needed to confirm these findings and 468 decipher their pathogenic significance.

469 Funding 470 This work was supported by the European Regional Development Fund through the 471 RUNDENG project (number 20202640-0022937). The funder had no role in study design, data

472 collection and analysis, decision to publish, or preparation of the manuscript.

473

474 Data availability statement

475 All data produced in the present study are available upon reasonable request to the 476 authors.

477

478 Credit authorship contribution

479 Azizah Issop: Investigation, Interpretation of the data, Original draft writing - review 480 and editing. Antoine Bertolotti: Formal analysis, Supervision - review and editing. Yves-481 Marie Diarra: Formal analysis, Methodology - review and editing. Jean-christophe Maïza: 482 Investigation - review and editing. Eric Jarlet: Investigation - review and editing. Muriel 483 **Cogne:** Investigation - review and editing. **Eric Doussiet:** Investigation - review and editing. 484 Eric Magny: Investigation, Software - review and editing. Olivier Maillard: Formal 485 analysis, Project administration - review and editing. Epidengue Cohort Investigation 486 **Team:** Jeanne Belot, Mathilde Cadic, Mathys Carras, Romain Chane-Teng, Romane Crouzet, 487 David Hirschinger, Anne-Cecilia Etoa N'Doko, Azizah Issop, Mathilde Legros, Mamitiana 488 Randriamanana, Cédric Rosolen, Nolwenn Sautereau, Investigation - review and editing. 489 Estelle Nobécourt: Formal analysis, Supervision, Writing - review and editing. Patrick 490 Gérardin: Conceptualization, Data curation, Formal analysis, Methodology, Software, 491 Validation, Vizualisation, Writing – review and editing.

492

493 **Declaration of competing interest**

494 All authors would like to report that are not conflicts of interest in relation to this 495 research. All authors have signed the disclosure form for potential conflicts of interest.

496

497 Acknowledgments

The authors thank the emergency units of the University Hospital of Reunion and all collaborators of the EPIDENGUE project.

500 **References**

504

507

510

514

518

523

529

533

537

540

543

- Du M, Jing W, Liu M, Liu J. The global trends and regional differences in incidence of dengue infection from 1990 to 2019: an analysis from the Global Burden of Diseases of Study. Infect Dis Ther 2021; 10: 1625-43. https://dx.doi/10.1007/s40121-021-00470-2.
- 505 2) European Center for Disease Prevention and Control. Dengue worldwide overview.
 506 https://www.ecdc.europa.eu/en/dengue-monthly. [Accessed 4 April 2023].
- Semenza JC, Rocklöv J, Ebi KL. Climate change and cascading risks from infectious disease. Infect Dis Ther. 2022; 11:1371-90. https://dx.doi/10.1007/s40121-022-00647-3.
- 4) La Ruche G, Souares Y, Armengaud A, Peloux-Petiot F, Delaunay P, Despres P, et al.
 First two autochthonous dengue virus infections in metropolitan France, September
 2010. Euro Surveill 2010; 15: 19676. https://dx.doi/10.2807/ese.15.39.19676-en.
- 5) Cochet A, Calba C, Jourdain F, Grard G, Durand GA, Guinard A, et al. Autochthonous dengue in mainland France, 2022: geographical extension and incidence increase. Euro Surveill. 2022; 27: 2200818. https://dx.doi/10.2807/1560-7917.ES.2022.27.44.2200818.
- 519 6) Vanwambecke SO, Bennett SN, Kapan DD. Spatially disaggregated disease
 520 transmission risk: land use, land cover and risk of dengue transmission on the island of
 521 Ohau Trop Med Int Health 2011; 16: 174-85. https://dx.doi/10.1111.j1365522 3156.2010.02671.x
- 524 7) Santé Publique France. DENGUE. Point epidemiologique hebdomadaire, La Reunion, 7 525 decembre 2021. Sante publique France-Reunion 6 pp. 526 https://www.santepubliquefrance.fr/regions/ocean-indien/documents/bulletin-527 regional/2021/surveillance-de-la-dengue-a-la-reunion.-point-au-7-decembre-2021. 528 [Accessed 4 April 2023].
- World Health Organization. Dengue guidelines for diagnosis, treatment, prevention and control : new edition. 2009. https://apps.who.int/iris/handle/10665/44188. [Accessed 4 April 2023].
- Joshi N, Caputo GM, Weitekamp MR, Karchmer AW. Infections in patients with diabetes mellitus. N Engl J Med. 1999; 341: 12.
 https://dx.doi/10.1056/NEJM199912163412507.
- Bertoni AG, Saydah S, Brancati FL. Diabetes and the risk of infection-related mortality
 in the U.S. Diabetes Care. 2001; 24: 1044–9. https://dx.doi/ 10.2337/diacare.24.6.1044.
- 541 11) Shah BR, Hux JE. Quantifying the risk of infectious diseases for people with diabetes.
 542 Diabetes Care. 2003;26: 510–3. https://dx.doi/10.2337/diacare.26.2.510.
- 544 12) Htun NSN, Odermatt P, Eze IC, Boillat-Blanco N, D'Acremont V, Probst-Hensch N. Is 545 diabetes a risk factor for a severe clinical presentation of dengue? - Review and meta-546 analysis. PLoS Negl Trop Dis. 2015; 9: e0003741. https://dx.doi/ 547 10.1371/journal.pntd.0003741.
- 548
- 549 13) Pang J, Salim A, Lee VJ, Hibberd ML, Chia KS, Leo YS, et al. Diabetes with

550 551 552		hypertension as risk factors for adult dengue hemorrhagic fever in a predominantly dengue serotype 2 epidemic: a case control study. PLoS Negl Trop Dis. 2012; 6: e1641. https://dx.doi/10.1371/journal.pntd.0001641.
553 554 555 556	14)	ORS La Réunion. ors_chiffres_diabete_reunion_2021.pdf. 2021. https://www.ors-reunion.fr/IMG/pdf/ors_chiffres_diabete_reunion_2021.pdf.
557 558 559 560	15)	Brown GW, Mood AM. On median tests for linear hypotheses. In: Proceeding of the second Berkeley symposium on mathematical statistics and probability, University of California Press ed, Berkeley, 1951: pp 159-66.
561 562 563 564	16)	Chamberlain G. Quantile regression, censoring, and the structure of wages. In: Advances in Economics Sixth World Congress, Cambridge University Press Sims CA ed, Cambridge 1994: pp 171-209.
565 566 567	17)	Zou G. A modified poisson regression approach to prospective studies with binary data. Am J Epidemiol 2004; 159(7): 702 6. https://dx.doi/10.1093/AJE/KWH090.
568 569 570 571	18)	Riley RD, Ensor J, Snell KIE, Harrell Jr FE, Martin GP, Reitsma JB, et al. Calculating the sample size required for developing a clinical prediction model. BMJ 2020; 368:m441 https://dx.doi/10.1136/bmj.m441.
572 573 574 575	19)	Badawi A, Ryoo SG, Vasileva D, Yaghoubi S. Prevalence of comorbidities in Chikungunya : a systematic review and meta-analysis. Int J Infect Dis. 2018; 67: 107-13. https://dx.doi/10.1016/j.ijid.2017.12.018 1201-9.
576 577 578 579	20)	Badawi A, Ryoo SG, Vasileva D, Yaghoubi S. Prevalence of comorbidities in dengue fever and West Nile virus: a systematic review and meta-analysis. PLoS One 2018; 13: e0200200. https://dx.doi/10.1371/journal.pone.0200200.
580 581 582 583 584	21)	Longmore DK, Miller JE, Bekkering S, Saner C, Mifsud E, Zhu Y et al. Diabetes and overweight/obesity are independent, nonadditive risk factors for in-hospital severity of COVID-19: an international, multicenter, retrospective meta-analysis. Diabetes Care 2021; 44: 1281-90. https://dx.doi/ 10.2337/dc20-2676.
585 586 587 588 588 589	22)	Favier F, Jaussent I, Moullec NL, Debussche X, Boyer M-C, Schwager J-C, et al. Prevalence of Type 2 diabetes and central adiposity in La Réunion Island, the REDIA Study. Diabetes Res Clin Pract. 2005;67: 234–242. https://dx.doi/10.1016/j.diabres.2004.07.013.
590 591 592 593	23)	Correa R, Ortega-Loubon C, Zapata-Castro LE, Armien B, Culquichicon C. Dengue with hemorhagic and acute pancreatitis: case report and review. Cureus 2019; 11: e4895. https://dx.doi/10.7759/cureus.4895.
594 595 596 597	24)	Venkatesan A, Tunkel AR, Bloch KC, Lauring AS, Sejvar J, Bitnun A, et al. Case definitions, diagnostic algorithms, and priorities in encephalitis : consensus statement of the International Encephalitis Consortium. Clin Infect Dis 2013; 57: 1114-28. https://dx.doi/10.1093/cid/cit458.
598 599	25)	Jean CM, Honarmand S, Louie JK, Glaser CA. Risk factors for West Nile virus

600 neuroinvasive disease, California, 2005. Emerg Infect Dis 2007; 13:1918-20. 601 https://dx.doi/10.3201/eid1312.061265. 602 603 Mehdi U, Toto RD. Anemia, diabetes, and chronic kidney disease. Diabetes Care 2009; 26) 604 32: 1320-6. https://dx.doi/10.2337/dc08-0779. 605 606 Romane Crouzet. [Facteurs de risque de décès ou de thérapeutique invasive chez les 27) 607 patients suspects de dengue durant l'épidémie à La Réunion en 2019]. In: HAL-608 Réunion. Archive ouverte de l'Université de La Réunion, ed. Sciences du Vivant [a-bio] 609 Dumas-03831531, v1. 2022, 79 pp. https://hal.univ-reunion.fr/dumas-03831531v1 610 611 Osuna-Ramos JF, Reyes-Ruiz JM, Ochoa-Ramírez LA, De Jesús-González LA, Ramos-28) 612 Payán R, Farfan-Morales CN. The usefulness of peripheral blood cell counts to distinguish COVID-19 from dengue during acute infection. Trop Med Infect Dis 2022; 613 614 7: 20. https://dx.doi/10.3390/tropicalmed7020020. 615 616 29) Garisha F, Rother N, Riswari SF, Alisjabaah B, Overheul GJ, van Rij RP, et al. 617 Neutrophil extracellular traps in dengue are mainly generated NOX-independently. 618 Front Immunol 2021; 12: 629167. https://dx.doi/10.3389/fimmu.2021.629167. 619 620 30) Njeim R, Azar WS, Fares AH, Azar ST, Kfoury Kassouf H, Eid AA. NETosis 621 contributes to the pathogenesis of diabetes and its complications. J Mol Endocrinol 622 2020; 65: R65- R76. https://dx.doi/10.1530/JME-20-0128. 623 624 31) Gurugama P, Jayarajah U, Wanigasuriya K, Wijewickrama A, Perera J, Seneviratne SL. 625 Renal manifestations of dengue virus infections. J Clin Virol. 2018; 101: 1-6. 626 https://dx.doi/10.1016/j.jcv.2018.01.001. 627 628 Mallhi TH, Khan AH, Adnan AS, Sarriff A, Khan YH, Jummaat F. Incidence, 32) 629 characteristics and risk factors of acute kidney injury among dengue patients: a 630 retrospective analysis. PLoS One 2015; 10: e0138465. 631 https://dx.doi/10.1371/journal.pone.0138465. 632 633 33) Stengel B, Jaussent I, Guiserix J, Bourgeon B, Papoz L, Favier F. High prevalence of 634 chronic kidney disease in La Réunion island and its association with the metabolic 635 syndrome in the non-diabetic population: La Réunion Diabetes (REDIA) Study. 636 Diabetes Metab. 2007; 33: 444–52. https://dx.doi/10.1016/j.diabet.2007.10.002. 637 638 Cournot M, Lenclume V, Le Moullec N, Debussche X, Doussiet E, Fagot-Campagna A, 34) 639 Favier F. Prevalence, treatment, and control of hypertension in La Réunion: the REDIA 640 population-based cohort study. Blood Press 2017; 26: 39-47. 641 https://dx.doi/10.1080/08037051.2016.1182854. 642 643 35) Limonta D, Torres G, Capó V, Guzmán MG. Apoptosis, vascular leakage and increased 644 risk of severe dengue in a type 2 diabetes mellitus patient. Diab Vasc Dis Res. 2008; 5: 645 213-4. https://dx.doi/ 10.3132/dvdr.2008.034. 646 647 Shen TJ, Chen CL, Tsai TT, Jhan MK, Bai CH, Yen YC, et al. Hyperglycemia 36) 648 exacerbates dengue virus infection by facilitating poly(A)-binding protein-mediated 649 Insight 2022; viral translation. JCI 7: e142805.

- 650 https://dx.doi/10.1172/jci.insight.142805.
- 651
- 652 37) Singh R, Goyal S, Aggarwal N, Mehta S, Kumari P, SinghV, et al. Study on dengue 653 severity in diabetic and non-diabetic population of tertiary care hospital by assessing 654 inflammatory indicators. Ann Med Surg (Lond) 2022; 82: 104710. 655 https://dx.doi/10.1016/j.amsu.2022.104710.
- Gawaz M, Neumann FJ, Dickfeld T, Koch W, Laugwitz KL, Adelsberger H, et al.
 Activated platelets induce monocyte chemotactic protein-1 secretion and surface expression of intercellular adhesion molecule-1 on endothelial cells. Circulation 1998; 98: 1164-71. https://dx.doi/10.1161/01.cir.98.12.1164.
- 661

666

656

- Lee IK, Hsieh C-J, Lee CT, Liu JW. Diabetic patients suffering dengue are at risk for
 development of dengue shock syndrome/severe dengue: Emphasizing the impacts of coexisting comorbidity(ies) and glycemic control on dengue severity. J Microbiol
 Immunol Infect. 2020; 53: 69–78. https://dx.doi/10.1016/j.jmii.2017.12.005.
- 40) Sangkaew S, Ming D, Boonyasiri A, Honeyford K, Kalayanarooj S, Yacoub S, et al.
 Risk predictors of progresion to severe diseases during the febrile phase of dengue: a
 systematic review and meta-analysis. Lancet Infect Dis 2021; 21: 1014-26.
 https://dx.doi/10.1016/S1473-3099(20)30601-0.
- 672 41) Chang K, Huang CH, Chen TC, Lin CY, Lu PL, Chen YH. Clinical characteristics and risk factors for intracranial haemorrhage or infarction in patients with dengue. J Microbiol Immunol Infect 2021; 54: 885-92. https://dx.doi/10.1016/j.jmii.2021.03.009.
- 675

671

⁴²⁾ Temprasertrudee S, Thanachartwet V, Desakorn V, Keatkla J, Chantratita W,
Kiertinuranakul S. A multicenter study of clinical presentations and predictive factors
for severe manifestations of dengue in adults. Jpn J Infect Dis 2018; 71: 239-43.
tps://dx.doi/10.7883/yoken.JJID.2017.457.

